Research programme: GPC3 targeting T cell therapies - TCR2 Therapeutics
Latest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator TCR2 Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 01 Jun 2023 TCR2 Therapeutics has been acquired by Adaptimmune
- 15 Jul 2021 GPC3 targeting antineoplastics are available for licensing as of 15 Jul 2021. https://www.tcr2.com/mission